221 related articles for article (PubMed ID: 37382397)
1. Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges.
Dignass A; Rath S; Kleindienst T; Stallmach A
Aliment Pharmacol Ther; 2023 Sep; 58(5):492-502. PubMed ID: 37382397
[TBL] [Abstract][Full Text] [Related]
2. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Turner D; Ricciuto A; Lewis A; D'Amico F; Dhaliwal J; Griffiths AM; Bettenworth D; Sandborn WJ; Sands BE; Reinisch W; Schölmerich J; Bemelman W; Danese S; Mary JY; Rubin D; Colombel JF; Peyrin-Biroulet L; Dotan I; Abreu MT; Dignass A;
Gastroenterology; 2021 Apr; 160(5):1570-1583. PubMed ID: 33359090
[TBL] [Abstract][Full Text] [Related]
3. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further?
Dal Buono A; Roda G; Argollo M; Zacharopoulou E; Peyrin-Biroulet L; Danese S
Expert Rev Gastroenterol Hepatol; 2020 Sep; 14(9):807-817. PubMed ID: 32762582
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.
Colombel JF; D'haens G; Lee WJ; Petersson J; Panaccione R
J Crohns Colitis; 2020 Feb; 14(2):254-266. PubMed ID: 31403666
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
7. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
Wu JF
Gut Liver; 2022 Jul; 16(4):515-524. PubMed ID: 34670875
[TBL] [Abstract][Full Text] [Related]
9. Review of Saccharomyces boulardii as a treatment option in IBD.
Sivananthan K; Petersen AM
Immunopharmacol Immunotoxicol; 2018 Dec; 40(6):465-475. PubMed ID: 29771163
[TBL] [Abstract][Full Text] [Related]
10. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Peyrin-Biroulet L; Sandborn W; Sands BE; Reinisch W; Bemelman W; Bryant RV; D'Haens G; Dotan I; Dubinsky M; Feagan B; Fiorino G; Gearry R; Krishnareddy S; Lakatos PL; Loftus EV; Marteau P; Munkholm P; Murdoch TB; Ordás I; Panaccione R; Riddell RH; Ruel J; Rubin DT; Samaan M; Siegel CA; Silverberg MS; Stoker J; Schreiber S; Travis S; Van Assche G; Danese S; Panes J; Bouguen G; O'Donnell S; Pariente B; Winer S; Hanauer S; Colombel JF
Am J Gastroenterol; 2015 Sep; 110(9):1324-38. PubMed ID: 26303131
[TBL] [Abstract][Full Text] [Related]
11. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last.
Le Berre C; Ricciuto A; Peyrin-Biroulet L; Turner D
Gastroenterology; 2022 Apr; 162(5):1424-1438. PubMed ID: 34995529
[TBL] [Abstract][Full Text] [Related]
12. Biologics in Pediatric Inflammatory Bowel Disease.
Kleinhenz J; Wagner E
Pediatr Ann; 2022 Feb; 51(2):e77-e81. PubMed ID: 35156888
[TBL] [Abstract][Full Text] [Related]
13. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.
Christensen B; Rubin DT
Curr Gastroenterol Rep; 2016 Jan; 18(1):5. PubMed ID: 26759147
[TBL] [Abstract][Full Text] [Related]
14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review.
Cao WT; Huang R; Jiang KF; Qiao XH; Wang JJ; Fan YH; Xu Y
World J Gastroenterol; 2021 Mar; 27(9):886-907. PubMed ID: 33727776
[TBL] [Abstract][Full Text] [Related]
16. Future directions in inflammatory bowel disease management.
D'Haens GR; Sartor RB; Silverberg MS; Petersson J; Rutgeerts P
J Crohns Colitis; 2014 Aug; 8(8):726-34. PubMed ID: 24742736
[TBL] [Abstract][Full Text] [Related]
17. Management of inflammatory bowel disease in children: It is time for an individualised approach.
Grover Z; Alex G
J Paediatr Child Health; 2020 Nov; 56(11):1677-1684. PubMed ID: 31613039
[TBL] [Abstract][Full Text] [Related]
18. [Role of anti-TNF therapy (biologics) in the treatment of chronic inflammatory bowel disease in children].
Kolacek S
Acta Med Croatica; 2013 Apr; 67(2):89-92. PubMed ID: 24471292
[TBL] [Abstract][Full Text] [Related]
19. Intestinal Barrier Healing Is Superior to Endoscopic and Histologic Remission for Predicting Major Adverse Outcomes in Inflammatory Bowel Disease: The Prospective ERIca Trial.
Rath T; Atreya R; Bodenschatz J; Uter W; Geppert CE; Vitali F; Fischer S; Waldner MJ; Colombel JF; Hartmann A; Neurath MF
Gastroenterology; 2023 Feb; 164(2):241-255. PubMed ID: 36279923
[TBL] [Abstract][Full Text] [Related]
20. Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say?
D'Arcangelo G; Aloi M
Paediatr Drugs; 2020 Oct; 22(5):463-472. PubMed ID: 32572841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
